Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Minuti

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.
Lung Cancer (Amsterdam, Netherlands)|April 8, 2025
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional studyAlice Avancini, Niccolò Giaj-Levra, Gabriele Minuti, et al.
Cancer Treatment Reviews|November 22, 2025
Bone metastases in NSCLC: Modern paradigms in management and supportive careGabriele Minuti, Giorgia Pasqualini, Alice Avancini, et al.
Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancerLorenza Landi, Federica D'Incà, Alain Gelibter, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT TrialFederico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.
Lung Cancer (Amsterdam, Netherlands)|April 8, 2025
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional studyAlice Avancini, Niccolò Giaj-Levra, Gabriele Minuti, et al.
Cancer Treatment Reviews|November 22, 2025
Bone metastases in NSCLC: Modern paradigms in management and supportive careGabriele Minuti, Giorgia Pasqualini, Alice Avancini, et al.
Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring <i>MET</i> exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancerLorenza Landi, Federica D'Incà, Alain Gelibter, et al.
Clinical Lung Cancer|September 23, 2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitorsLorenza Landi, Marcello Tiseo, Rita Chiari, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT TrialFederico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Pageof 5